| Elizabeth G Biggers, DO | |
|
538 Wilbur St, Brandon, FL 33511-4885 | |
| (813) 655-4646 | |
| (855) 366-8430 |
| Full Name | Elizabeth G Biggers |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 18 Years |
| Location | 538 Wilbur St, Brandon, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588863021 | NPI | - | NPPES |
| 000874500 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | OS10147 (Florida) | Secondary |
| 207Q00000X | Family Medicine | OS10147 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sports And Orthopedic Rehabilitation Services Inc | 0840104253 | 192 |
| Biggers Family Medicine, P.a. | 1658538947 | 3 |
News Archive
The news that people being treated for suspected bird flu in India and Malaysia, do not in fact have the virus will come as a relief to many and calm fear that the disease has spread to humans.
Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.
Scientists at Weill Cornell Medical College have discovered the molecular switch that allows aggressive triple negative breast cancer cells to grow the amoeba-like protrusions they need to crawl away from a primary tumor and metastasize throughout the body. Their findings, published in Cancer Cell, suggest a novel approach for developing agents to treat cancer once it has spread.
For rodent pups, bonding with mom isn't hard-wired in the womb. It develops over the first few weeks of life, which is achieved by their maturing sense of smell, possibly allowing these mammals a survival advantage by learning to identify mother, siblings, and home.
› Verified 3 days ago
| Entity Name | Biggers Family Medicine, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639453582 PECOS PAC ID: 1658538947 Enrollment ID: O20120127000692 |
News Archive
The news that people being treated for suspected bird flu in India and Malaysia, do not in fact have the virus will come as a relief to many and calm fear that the disease has spread to humans.
Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.
Scientists at Weill Cornell Medical College have discovered the molecular switch that allows aggressive triple negative breast cancer cells to grow the amoeba-like protrusions they need to crawl away from a primary tumor and metastasize throughout the body. Their findings, published in Cancer Cell, suggest a novel approach for developing agents to treat cancer once it has spread.
For rodent pups, bonding with mom isn't hard-wired in the womb. It develops over the first few weeks of life, which is achieved by their maturing sense of smell, possibly allowing these mammals a survival advantage by learning to identify mother, siblings, and home.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth G Biggers, DO 538 Wilbur St, Brandon, FL 33511-4885 Ph: (813) 655-4646 | Elizabeth G Biggers, DO 538 Wilbur St, Brandon, FL 33511-4885 Ph: (813) 655-4646 |
News Archive
The news that people being treated for suspected bird flu in India and Malaysia, do not in fact have the virus will come as a relief to many and calm fear that the disease has spread to humans.
Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.
Scientists at Weill Cornell Medical College have discovered the molecular switch that allows aggressive triple negative breast cancer cells to grow the amoeba-like protrusions they need to crawl away from a primary tumor and metastasize throughout the body. Their findings, published in Cancer Cell, suggest a novel approach for developing agents to treat cancer once it has spread.
For rodent pups, bonding with mom isn't hard-wired in the womb. It develops over the first few weeks of life, which is achieved by their maturing sense of smell, possibly allowing these mammals a survival advantage by learning to identify mother, siblings, and home.
› Verified 3 days ago
Dr. Sandra Dorsey, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 122 South Moon Avenue, Brandon, FL 33511 Phone: 813-438-8937 | |
Dr. Jose A Berrios, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 320 Oakfield Drive Suite D, Brandon, FL 33511 Phone: 813-657-1064 Fax: 813-654-7105 | |
Dr. Adolfo Salvador Galvez, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1002 John Moore Rd, Brandon, FL 33511 Phone: 813-684-6771 | |
Anh Dinh-kim, M.D Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 119 Oakfield Dr, Brandon, FL 33511 Phone: 813-681-5551 | |
Tahir Hussain Rizvi, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 119 Oakfield Dr, Brandon, FL 33511 Phone: 855-421-2733 Fax: 321-280-2479 | |
Aaron W Guthrie, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 519a E Bloomingdale Ave Ste A, Brandon, FL 33511 Phone: 813-655-4100 Fax: 813-655-1775 | |
Brunilda Nazario, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1989 W Lumsden Rd, Brandon, FL 33511 Phone: 813-653-3111 Fax: 813-653-1384 |